You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxymorphone
Accession NumberDB01192  (APRD00158)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionAn opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)
Structure
Thumb
Synonyms
14-Hydroxydihydromorphinone
Dihydrohydroxymorphinone
Dihydroxymorphinone
EN3202
Numorphan
Opana
Oximorphonum
Oxymorphine
Oxymorphone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Numorphan Injection 1.5mg/mlliquid1.5 mgintramuscular; intravenous; subcutaneousBristol Myers Squibb Canada1993-12-312004-08-04Canada
Numorphan Suppository 5mgsuppository5 mgrectalBristol Myers Squibb Canada1993-12-312002-07-04Canada
Opanainjection1 mg/mLintramuscular; intravenous; subcutaneousEndo Pharmaceuticals Inc.1959-06-01Not applicableUs
Opanatablet5 mg/1oralbryant ranch prepack2006-06-26Not applicableUs
Opanatablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-09Not applicableUs
Opanatablet5 mg/1oralEndo Pharmaceuticals2006-06-26Not applicableUs
Opanatablet10 mg/1oralSTAT Rx USA LLC2011-12-15Not applicableUs
Opanatablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-09Not applicableUs
Opanatablet10 mg/1oralEndo Pharmaceuticals2006-06-26Not applicableUs
Opana ERtablet (extended-release)20 mgoralPaladin Labs IncNot applicableNot applicableCanada
Opana ERtablet, extended release10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Opana ERtablet, extended release30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERtablet, film coated, extended release40 mg/1oralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERtablet, extended release15 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet, film coated, extended release5 mg/1oralRebel Distributors Corp2006-06-22Not applicableUs
Opana ERtablet, extended release5 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet (extended-release)40 mgoralPaladin Labs IncNot applicableNot applicableCanada
Opana ERtablet, extended release20 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-10Not applicableUs
Opana ERtablet20 mg/1oralbryant ranch prepack2010-12-31Not applicableUs
Opana ERtablet, film coated, extended release10 mg/1oralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERtablet, extended release10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERtablet, extended release20 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet (extended-release)5 mgoralPaladin Labs IncNot applicableNot applicableCanada
Opana ERtablet, film coated, extended release10 mg/1oralRebel Distributors Corp2006-06-22Not applicableUs
Opana ERtablet, extended release7.5 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet, extended release40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Opana ERtablet20 mg/1oralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
Opana ERtablet, extended release40 mg/1oralbryant ranch prepack2006-06-30Not applicableUs
Opana ERtablet, extended release20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERtablet, extended release30 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet (extended-release)10 mgoralPaladin Labs IncNot applicableNot applicableCanada
Opana ERtablet, extended release10 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Opana ERtablet, extended release30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs
Opana ERtablet, film coated, extended release5 mg/1oralSTAT Rx USA LLC2006-06-22Not applicableUs
Opana ERtablet, extended release40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Opana ERtablet, extended release40 mg/1oralEndo Pharmaceuticals Inc.2012-03-20Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralQualitest Pharmaceuticals2010-09-29Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralAmerican Health Packaging2015-12-21Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralQualitest Pharmaceuticals2010-09-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oxymorphone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-29Not applicableUs
Oxymorphone Hydrochloridetablet, extended release40 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release10 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc2010-09-27Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release15 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.2012-12-10Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralMallinckrodt, Inc.2012-04-12Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release15 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet, extended release5 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralCore Pharma, Llc2015-01-17Not applicableUs
Oxymorphone Hydrochloridetablet, extended release15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, extended release7.5 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release20 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc2010-09-27Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release20 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release30 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release5 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralMallinckrodt, Inc.2012-04-12Not applicableUs
Oxymorphone Hydrochloridetablet, extended release10 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralCore Pharma, Llc2015-01-17Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralKvk Tech, Inc.2013-02-11Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-02-11Not applicableUs
Oxymorphone Hydrochloridetablet, extended release15 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release40 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet5 mg/1oralTeva Pharmaceuticals USA Inc2013-04-11Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release30 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release7.5 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet, extended release20 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release5 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralKvk Tech, Inc.2013-02-11Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-02-11Not applicableUs
Oxymorphone Hydrochloridetablet, extended release30 mg/1oralActavis Elizabeth LLC2010-12-31Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release7.5 mg/1oralImpax Generics2013-01-02Not applicableUs
Oxymorphone Hydrochloridetablet10 mg/1oralTeva Pharmaceuticals USA Inc2013-04-11Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release40 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloridetablet, film coated, extended release10 mg/1oralRanbaxy Pharmaceuticals Inc.2015-04-13Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release20 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release30 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release40 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release7.5 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release5 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release15 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Oxymorphone Hydrochloride Extended-releasetablet, extended release10 mg/1oralMallinckrodt, Inc.2014-06-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NumorphanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxymorphone hydrochloride
ThumbNot applicableDBSALT001249
Categories
UNII9VXA968E0C
CAS number76-41-5
WeightAverage: 301.3371
Monoisotopic: 301.131408101
Chemical FormulaC17H19NO4
InChI KeyInChIKey=UQCNKQCJZOAFTQ-ISWURRPUSA-N
InChI
InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1
IUPAC Name
(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • 1,2-aminoalcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of moderate-to-severe pain.
PharmacodynamicsOxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.
Mechanism of actionOxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. Also, it has been shown that oxymorphone binds to and inhibits GABA inhibitory interneurons via mu-receptors. These interneurons normally inhibit the descending pain inhibition pathway. So, without the inhibitory signals, pain modulation can proceed downstream.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Oxymorphone undergoes extensive hepatic metabolism in humans. After a 10 mg oral dose, 49% was excreted over a five-day period in the urine. Of this, 82% was excreted in the first 24 hours after administration. The recovered drug-related products contained the oxymorphone (1.9%), the conjugate of oxymorphone (44.1%), the 6(beta)-carbinol produced by 6-keto reduction of oxymorphone (0.3%), and the conjugates of 6(beta)-carbinol (2.6%) and 6(alpha)-carbinol (0.1%).

SubstrateEnzymesProduct
Oxymorphone
noroxycodoneDetails
Oxymorphone
noroxymorphoneDetails
Oxymorphone
alpha-noroxycodolDetails
Oxymorphone
beta-noroxycodolDetails
Oxymorphone
oxymorphoneDetails
Oxymorphone
beta-oxymorpholDetails
Oxymorphone
alpha-oxycodolDetails
Oxymorphone
beta-oxycodolDetails
Route of eliminationOxymorphone is highly metabolized, principally in the liver, and undergoes reduction or conjugation with glucuronic acid to form both active and inactive products. Because oxymorphone is extensively metabolized, <1% of the administered dose is excreted unchanged in the urine.
Half life1.3 (+/-0.7) hours
ClearanceNot Available
ToxicityOxymorphone overdosage is characterized by respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In a severe case of overdose, apnea, circulatory collapse, cardiac arrest, and death may occur. Intravenous mouse LD50 is 172 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxymorphone Action PathwayDrug actionSMP00412
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7798
P-glycoprotein substrateSubstrate0.9112
P-glycoprotein inhibitor INon-inhibitor0.8887
P-glycoprotein inhibitor IINon-inhibitor0.9734
Renal organic cation transporterNon-inhibitor0.5585
CYP450 2C9 substrateNon-substrate0.8014
CYP450 2D6 substrateSubstrate0.8105
CYP450 3A4 substrateSubstrate0.7439
CYP450 1A2 substrateNon-inhibitor0.8796
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorNon-inhibitor0.7168
CYP450 2C19 inhibitorNon-inhibitor0.8455
CYP450 3A4 inhibitorNon-inhibitor0.9219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9812
Ames testNon AMES toxic0.6663
CarcinogenicityNon-carcinogens0.9635
BiodegradationNot ready biodegradable0.9758
Rat acute toxicity2.9920 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9345
hERG inhibition (predictor II)Non-inhibitor0.9374
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous; subcutaneous1.5 mg
Suppositoryrectal5 mg
Injectionintramuscular; intravenous; subcutaneous1 mg/mL
Tabletoral20 mg/1
Tablet (extended-release)oral10 mg
Tablet (extended-release)oral20 mg
Tablet (extended-release)oral40 mg
Tablet (extended-release)oral5 mg
Tablet, film coated, extended releaseoral10 mg/1
Tablet, film coated, extended releaseoral40 mg/1
Tablet, film coated, extended releaseoral5 mg/1
Tabletoral10 mg/1
Tabletoral5 mg/1
Tablet, extended releaseoral10 mg/1
Tablet, extended releaseoral15 mg/1
Tablet, extended releaseoral20 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral40 mg/1
Tablet, extended releaseoral5 mg/1
Tablet, extended releaseoral7.5 mg/1
Tablet, film coated, extended releaseoral15 mg/1
Tablet, film coated, extended releaseoral20 mg/1
Tablet, film coated, extended releaseoral30 mg/1
Tablet, film coated, extended releaseoral7.5 mg/1
Prices
Unit descriptionCostUnit
Opana er 40 mg tablet21.82USD tablet
Opana er 30 mg tablet17.39USD tablet
Opana ER 40 mg 12 Hour tablet12.42USD tablet
Opana er 20 mg tablet12.12USD tablet
Opana ER 30 mg 12 Hour tablet9.76USD tablet
Opana er 15 mg tablet9.26USD tablet
Opana ER 20 mg 12 Hour tablet7.17USD tablet
Opana ER 15 mg 12 Hour tablet5.82USD tablet
Opana er 5 mg tablet5.53USD tablet
Opana ER 10 mg 12 Hour tablet4.4USD tablet
Opana er 10 mg tablet3.95USD tablet
Opana ER 7.5 mg 12 Hour tablet3.3USD tablet
Numorphan 1 mg/ml ampul3.13USD ml
Opana er 7.5 mg tablet3.0USD tablet
Opana ER 5 mg 12 Hour tablet2.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5662933 No1993-09-092013-09-09Us
US7276250 No2003-02-042023-02-04Us
US7851482 No2009-07-102029-07-10Us
US8075872 No2003-11-202023-11-20Us
US8114383 No2004-08-082024-08-08Us
US8192722 No2005-09-152025-09-15Us
US8309060 No2003-11-202023-11-20Us
US8309122 No2003-02-042023-02-04Us
US8329216 No2003-02-042023-02-04Us
US8808737 No2007-06-212027-06-21Us
US8871779 No2009-11-222029-11-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-249 °CPhysProp
water solubility2.4E+004 mg/LNot Available
logP0.83HANSCH,C ET AL. (1995)
pKa8.17SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility25.6 mg/mLALOGPS
logP1.26ALOGPS
logP0.78ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)7.34ChemAxon
pKa (Strongest Basic)10.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area70 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.56 m3·mol-1ChemAxon
Polarizability30.77 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udl-7932000000-89141254d526ca629dacView in MoNA
References
Synthesis Reference

Bao-Shan Huang, Yansong Lu, Ben-Yi Ji, Aris P Christodoulou, “Preparation of oxymorphone from morphine.” U.S. Patent US5922876, issued May, 1992.

US5922876
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (9.95 MB)
MSDSDownload (133 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxymorphone.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Oxymorphone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Oxymorphone is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Oxymorphone can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Oxymorphone.
AcepromazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxymorphone.
adipiplonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxymorphone.
AlimemazineAlimemazine may increase the hypotensive activities of Oxymorphone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxymorphone.
AlvimopanThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amiloride.
AmiodaroneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Oxymorphone which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amobarbital.
AmoxapineOxymorphone may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Oxymorphone.
AmperozideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Oxymorphone.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Oxymorphone.
AprepitantThe serum concentration of Oxymorphone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.
ArtemetherThe metabolism of Oxymorphone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Asenapine.
AtazanavirThe metabolism of Oxymorphone can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Oxymorphone can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxymorphone.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Oxymorphone.
AzaperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azaperone.
AzelastineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxymorphone.
AzosemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxymorphone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benmoxin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Oxymorphone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Oxymorphone.
BenzphetamineBenzphetamine may increase the analgesic activities of Oxymorphone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benzyl alcohol.
BetaxololThe metabolism of Oxymorphone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Oxymorphone can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Oxymorphone.
BoceprevirThe metabolism of Oxymorphone can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Oxymorphone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Oxymorphone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
BrimonidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxymorphone.
BuprenorphineBuprenorphine may decrease the analgesic activities of Oxymorphone.
BuprenorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Buprenorphine.
BupropionThe metabolism of Oxymorphone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxymorphone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone.
ButacaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Oxymorphone.
ButorphanolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxymorphone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Caroxazone.
CelecoxibThe metabolism of Oxymorphone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Oxymorphone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxymorphone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Oxymorphone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxymorphone.
ChloroquineThe metabolism of Oxymorphone can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Oxymorphone.
ChlorphentermineChlorphentermine may increase the analgesic activities of Oxymorphone.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Oxymorphone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Oxymorphone can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Oxymorphone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Oxymorphone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxymorphone.
CitalopramOxymorphone may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Oxymorphone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Oxymorphone can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Oxymorphone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clidinium.
ClobazamThe metabolism of Oxymorphone can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with clomethiazole.
ClomipramineOxymorphone may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Oxymorphone can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxymorphone.
ClotrimazoleThe metabolism of Oxymorphone can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Oxymorphone can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clozapine.
CobicistatThe serum concentration of Oxymorphone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxymorphone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxymorphone.
ConivaptanThe serum concentration of Oxymorphone can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Conivaptan.
CrizotinibThe metabolism of Oxymorphone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxymorphone.
CyclosporineThe metabolism of Oxymorphone can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Oxymorphone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxymorphone.
DapoxetineOxymorphone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Oxymorphone.
DarunavirThe serum concentration of Oxymorphone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Oxymorphone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Oxymorphone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Oxymorphone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxymorphone.
DesipramineThe metabolism of Oxymorphone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxymorphone.
DesmopressinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Detomidine.
DexamethasoneThe serum concentration of Oxymorphone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Oxymorphone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxymorphone.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Oxymorphone.
DextromoramideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxymorphone.
DezocineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxymorphone.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.
DifenoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Oxymorphone can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine.
DiltiazemThe metabolism of Oxymorphone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Oxymorphone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxymorphone.
DoramectinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxepin.
DoxycyclineThe metabolism of Oxymorphone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
DoxylamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Oxymorphone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
DronedaroneThe metabolism of Oxymorphone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxymorphone.
DrospirenoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Drotebanol.
DuloxetineThe metabolism of Oxymorphone can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone.
EcgonineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxymorphone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Oxymorphone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Efonidipine.
EliglustatThe metabolism of Oxymorphone can be decreased when combined with Eliglustat.
EluxadolineOxymorphone may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxymorphone.
EntacaponeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Entacapone.
EnzalutamideThe serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Eplerenone.
ErythromycinThe metabolism of Oxymorphone can be decreased when combined with Erythromycin.
EscitalopramOxymorphone may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Oxymorphone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxymorphone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.
EthanolOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Oxymorphone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxymorphone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Oxymorphone.
EthosuximideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxymorphone.
EtoperidoneOxymorphone may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etorphine.
EtravirineThe serum concentration of Oxymorphone can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fencamfamine.
FenfluramineOxymorphone may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxymorphone.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Oxymorphone.
FexofenadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flibanserin.
FluconazoleThe metabolism of Oxymorphone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flunitrazepam.
FluoxetineOxymorphone may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Oxymorphone can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxymorphone.
FluphenazineFluphenazine may increase the hypotensive activities of Oxymorphone.
FluphenazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxymorphone.
FluspirileneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluticasone Propionate.
FluvoxamineOxymorphone may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Oxymorphone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Oxymorphone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Oxymorphone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fospropofol.
FurazolidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furazolidone.
FurosemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Furosemide.
Fusidic AcidThe serum concentration of Oxymorphone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxymorphone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Oxymorphone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxymorphone.
GuanfacineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxymorphone.
HaloperidolThe metabolism of Oxymorphone can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Oxymorphone.
HeroinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxymorphone.
HexobarbitalThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Oxymorphone.
HydracarbazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydracarbazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Oxymorphone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxymorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Oxymorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
HydroxyzineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Oxymorphone.
IdelalisibThe serum concentration of Oxymorphone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iloperidone.
ImatinibThe metabolism of Oxymorphone can be decreased when combined with Imatinib.
ImipramineThe metabolism of Oxymorphone can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Imipramine.
IndalpineOxymorphone may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.
IndinavirThe metabolism of Oxymorphone can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.
IproclozideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iproniazid.
IsavuconazoniumThe metabolism of Oxymorphone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxymorphone.
IsoniazidThe metabolism of Oxymorphone can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Isosorbide.
IsradipineThe metabolism of Oxymorphone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Oxymorphone can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Oxymorphone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone.
KetoconazoleThe metabolism of Oxymorphone can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Oxymorphone is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Oxymorphone.
LevocabastineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levomethadyl Acetate.
LevomilnacipranOxymorphone may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxymorphone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxymorphone.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Oxymorphone.
LithiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lofentanil.
LopinavirThe metabolism of Oxymorphone can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxymorphone.
LorcaserinThe metabolism of Oxymorphone can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Oxymorphone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxymorphone.
Lu AA21004Oxymorphone may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Oxymorphone.
LuliconazoleThe serum concentration of Oxymorphone can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Oxymorphone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mebanazine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.
MeclizineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Oxymorphone.
MelperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Oxymorphone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxymorphone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.
MersalylThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Oxymorphone.
MesoridazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.
MethadoneThe metabolism of Oxymorphone can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Oxymorphone.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Oxymorphone.
MethapyrileneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxymorphone.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Oxymorphone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxymorphone.
MethsuximideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methylene blue.
Methylene blueMethylene blue may increase the hypotensive activities of Oxymorphone.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Oxymorphone.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxymorphone.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Oxymorphone.
MetolazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.
MetoprololThe metabolism of Oxymorphone can be decreased when combined with Metoprolol.
MetyrosineOxymorphone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.
MifepristoneThe metabolism of Oxymorphone can be decreased when combined with Mifepristone.
MilnacipranOxymorphone may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
MirabegronThe metabolism of Oxymorphone can be decreased when combined with Mirabegron.
MirtazapineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxymorphone.
MitotaneThe serum concentration of Oxymorphone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.
ModafinilThe serum concentration of Oxymorphone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Oxymorphone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxymorphone.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Oxymorphone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.
NabiloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nabilone.
NafcillinThe serum concentration of Oxymorphone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Oxymorphone.
NalbuphineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nalbuphine.
NaloxegolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Naloxegol.
NaltrexoneThe therapeutic efficacy of Oxymorphone can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Oxymorphone can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Oxymorphone can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Oxymorphone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Oxymorphone can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nialamide.
NicardipineThe metabolism of Oxymorphone can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Oxymorphone can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Oxymorphone.
OctamoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Octamoxin.
OlanzapineOxymorphone may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxymorphone.
OlaparibThe metabolism of Oxymorphone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxymorphone.
OpiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Opium.
OrphenadrineOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxymorphone.
OsanetantThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Osanetant.
OsimertinibThe serum concentration of Oxymorphone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxymorphone.
OxprenololThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxymorphone.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Oxymorphone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Oxymorphone.
PalbociclibThe serum concentration of Oxymorphone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxymorphone.
PanobinostatThe metabolism of Oxymorphone can be decreased when combined with Panobinostat.
ParaldehydeOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Oxymorphone.
PargylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.
ParoxetineOxymorphone may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Oxymorphone can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.
PentazocinePentazocine may decrease the analgesic activities of Oxymorphone.
PentazocineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxymorphone.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Oxymorphone.
PerampanelThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Oxymorphone.
PerphenazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxymorphone.
PhenelzineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxymorphone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenoxypropazine.
PhenterminePhentermine may increase the analgesic activities of Oxymorphone.
PhenytoinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxymorphone.
PipamperoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Oxymorphone.
PipotiazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.
PiretanideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pirlindole.
PivhydrazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.
PosaconazoleThe metabolism of Oxymorphone can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium Citrate.
PramipexoleOxymorphone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxymorphone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxymorphone.
PrimidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxymorphone.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Oxymorphone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Oxymorphone.
PromazinePromazine may increase the hypotensive activities of Oxymorphone.
PromazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Oxymorphone.
PromethazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Oxymorphone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxymorphone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxymorphone.
PropoxycaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Oxymorphone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Oxymorphone.
QuinineThe metabolism of Oxymorphone can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ramelteon.
RamosetronOxymorphone may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Oxymorphone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxymorphone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxymorphone.
RifabutinThe metabolism of Oxymorphone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Oxymorphone can be increased when combined with Rifampicin.
RifapentineThe metabolism of Oxymorphone can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.
RitonavirThe metabolism of Oxymorphone can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Oxymorphone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Romifidine.
RopiniroleOxymorphone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Oxymorphone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone.
RotigotineOxymorphone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxymorphone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxymorphone is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Safrazine.
SaquinavirThe metabolism of Oxymorphone can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxymorphone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone.
SelegilineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sertindole.
SertralineOxymorphone may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Oxymorphone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sevoflurane.
SildenafilThe metabolism of Oxymorphone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Oxymorphone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Oxymorphone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Oxymorphone.
SpironolactoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Spironolactone.
St. John's WortThe serum concentration of Oxymorphone can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Oxymorphone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.
SulfisoxazoleThe metabolism of Oxymorphone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxymorphone.
SuvorexantThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tasimelteon.
TelaprevirThe metabolism of Oxymorphone can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Oxymorphone can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxymorphone.
TerbinafineThe metabolism of Oxymorphone can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrodotoxin.
ThalidomideOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxymorphone.
TheobromineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxymorphone.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxymorphone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxymorphone.
ThioridazineThioridazine may increase the hypotensive activities of Oxymorphone.
ThioridazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiagabine.
TiclopidineThe metabolism of Oxymorphone can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Oxymorphone.
TipranavirThe metabolism of Oxymorphone can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tizanidine.
TocilizumabThe serum concentration of Oxymorphone can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Toloxatone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Oxymorphone.
TolvaptanThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxymorphone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.
TranylcypromineThe metabolism of Oxymorphone can be decreased when combined with Tranylcypromine.
TrazodoneOxymorphone may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxymorphone.
TriamtereneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxymorphone.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Oxymorphone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Oxymorphone.
TriflupromazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxymorphone.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Oxymorphone.
TrimipramineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Oxymorphone.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Oxymorphone.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Oxymorphone.
UlaritideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Oxymorphone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxymorphone.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.
VenlafaxineThe metabolism of Oxymorphone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Oxymorphone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vigabatrin.
VilazodoneOxymorphone may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Oxymorphone can be decreased when combined with Voriconazole.
VortioxetineOxymorphone may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Oxymorphone.
XylazineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxymorphone.
ZiconotideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziconotide.
ZimelidineOxymorphone may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Oxymorphone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxymorphone.
ZonisamideThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Spetea M, Nevin ST, Hosztafi S, Ronai AZ, Toth G, Borsodi A: Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids. Neurochem Res. 1998 Sep;23(9):1211-6. [PubMed:9712193 ]
  2. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology. 2006 Oct;105(4):801-12. [PubMed:17006080 ]
  3. Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26. [PubMed:17595308 ]
  4. Halimi G, Devaux C, Clot-Faybesse O, Sampol J, Legof L, Rochat H, Guieu R: Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur J Pharmacol. 2000 Jun 16;398(2):217-24. [PubMed:10854833 ]
  5. Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F: Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery. Neurosci Lett. 2006 Mar 20;396(1):44-9. Epub 2005 Dec 15. [PubMed:16343768 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Chamberlin KW, Cottle M, Neville R, Tan J: Oral oxymorphone for pain management. Ann Pharmacother. 2007 Jul;41(7):1144-52. Epub 2007 Jun 26. [PubMed:17595308 ]
  2. Ananthan S, Khare NK, Saini SK, Seitz LE, Bartlett JL, Davis P, Dersch CM, Porreca F, Rothman RB, Bilsky EJ: Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12. [PubMed:14998329 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x. [PubMed:20642550 ]
  2. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. [PubMed:20590587 ]
  3. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006 May;79(5):461-79. [PubMed:16678548 ]
  4. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol. 2005 Mar;45(3):337-45. [PubMed:15703368 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87. doi: 10.1111/j.1365-2125.2010.03653.x. [PubMed:20642550 ]
  2. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. [PubMed:20590587 ]
  3. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006 May;79(5):461-79. [PubMed:16678548 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:27